Radiomics Signature Predicts the Recurrence-Free Survival in Stage I Non-Small-Cell Lung Cancer.
CONCLUSION: Radiomics signature may be an independent imaging biomarker for predicting the survival, which may guide for personalizing treatment option in patients with stage I NSCLC.
PMID: 32087134 [PubMed - as supplied by publisher]
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Authors: Wang T, Deng J, She Y, Zhang L, Wang B, Ren Y, Wu J, Xie D, Sun X, Chen C Tags: Ann Thorac Surg Source Type: research
More News: Cancer | Cancer & Oncology | Cardiovascular & Thoracic Surgery | CT Scan | Lung Cancer | Non-Small Cell Lung Cancer | Science | Study